Theravance (THRX) 14.85 $THRX
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 4:36PM CST
TTS: 8.57 (-0.27), HK: 2.18 (-0.02), BTU: 7.65 (+0.46), IRWD: 15.15 (-0.85), CAG: 34.83 (-1.59), LOGM: 52.22 (+4.17), PES: 5.74 (+0.54), THRX: 14.85 (+1.00), HOS: 20.45 (+1.52), EGY: 5.86 (-0.06)
Theravance: Notes From The Leerink Global Healthcare Conference
Early Retiree - at Seeking Alpha - Fri Feb 13, 9:01AM CST
THRX: 14.85 (+1.00)
5 Things GlaxoSmithKline PLC's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 12, 9:02AM CST
Source: GlaxoSmithKline, Facebook. The fourth quarter was another rough one for U.K.-based pharmaceutical giant GlaxoSmithKline . During the quarter, GlaxoSmithKline saw its revenue tumble 10% to $9.41 billion , inclusive of negative foreign...
JNJ: 99.62 (+1.18), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance to Report Fourth Quarter and Full Year 2014 Financial Results on February 18, 2015
Marketwired - Wed Feb 11, 3:07PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Wednesday, February 18, 2015.
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
Theravance (THRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:26AM CST
Theravance (THRX) Shares March Higher, Can It Continue?
THRX: 14.85 (+1.00)
Theravance/Glaxo's Asthma Drug Under FDA Panel Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:36PM CST
Theravance (THRX) and partner GlaxoSmithKline's (GSK) asthma drug, Breo Ellipta is scheduled to be reviewed by the FDA's advisory panel on Mar 19, 2015.
OPHT: 51.11 (+0.12), TBPH: 18.51 (+0.28), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00)
Theravance Biopharma: GSK Accelerates Study Of High-Potential COPD Therapy
Early Retiree - at Seeking Alpha - Mon Feb 09, 1:43PM CST
AZN: 69.96 (+0.20), TBPH: 18.51 (+0.28), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
Theravance's asthma NDA BREO ELLIPTA (FF/VI) to be reviewed by the US FDA Advisory Committee
M2 - Mon Feb 09, 6:19AM CST
Respiratory company Theravance (NASDAQ:THRX) said on Friday that the US Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will review the supplemental New Drug Application (NDA) for fluticasone furoate and vilanterol dry powder in asthma patients.
THRX: 14.85 (+1.00)
GSK and Theravance Announce Start of Phase III Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI for COPD
Marketwired - Mon Feb 09, 4:13AM CST
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study to evaluate the effects of the investigational once-daily closed triple combination of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with chronic obstructive pulmonary disease (COPD).
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
FDA Ad Comm to review expanded indication for Glaxo/Theravance COPD drug
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 9:06AM CST
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA(R) (FF/VI) for Asthma
Marketwired - Fri Feb 06, 8:10AM CST
Theravance, Inc. (NASDAQ: THRX) today announced that on March 19, 2015, the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will discuss the supplemental New Drug Application (NDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO(R) ELLIPTA(R)), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older. The advanced display of the Federal Register notice announcing the advisory committee meeting can be found at: http://www.ofr.gov/OFRUpload/OFRData/2015-02554_PI.pdf
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
6.73% Edge For 5 Healthcare Lowest-Priced, High-Yield January Dividend Dogs
Fredrik Arnold - at Seeking Alpha - Thu Feb 05, 6:43PM CST
SNN: 35.82 (-0.28), VIVO: 19.15 (+0.16), PETS: 15.57 (-0.05), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), PDLI: 7.28 (+0.03)
Theravance Royalty Revenue Forecast
Early Retiree - at Seeking Alpha - Thu Feb 05, 4:45PM CST
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance to Present at the Leerink Global Healthcare Conference
Marketwired - Thu Feb 05, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 11:10 a.m. EST. The conference will be held from February 11 - 12, 2015 at the Waldorf Astoria, New York, NY.
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
10 Hardy Healthcare Dividend Dogs Hit 20% Mean January Upsides
Fredrik Arnold - at Seeking Alpha - Wed Feb 04, 7:53PM CST
KND: 19.68 (-0.38), BDX: 143.71 (+0.72), VIVO: 19.15 (+0.16), PETS: 15.57 (-0.05), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), MSA: 46.51 (+0.21), MR: 27.19 (+0.15), PDLI: 7.28 (+0.03), SNN: 35.82 (-0.28), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), THRX: 14.85 (+1.00), SNY: 49.42 (+0.82)
GlaxoSmithKline PLC Earnings: Finally Turning a Corner?
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 2:18PM CST
Source: GlaxoSmithKline, Flickr. Normally earning season is a catalyst that can push stocks higher, and which investors eagerly await. For GlaxoSmithKline shareholders, however, earnings season has been an utter nightmare in recent quarters as...
PFE: 34.64 (-0.23), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance Down 57.2% Since SmarTrend Downtrend Call (THRX)
Comtex SmarTrend(R) - Wed Feb 04, 9:34AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 7 months, Theravance has returned 57.15% as of today's recent price of $11.71.
THRX: 14.85 (+1.00)
Critical Alerts For BlackBerry, Canadian Solar, Theravance, Petrobras and Halliburton Released By InvestorsObserver
PR Newswire - Wed Feb 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BBRY, CSIQ, THRX, PBR and HAL.
PBR: 6.98 (+0.44), BBRY: 10.09 (+0.23), HAL: 44.19 (+1.42), THRX: 14.85 (+1.00), CSIQ: 28.84 (-0.30)
Mylan Makes Deals In Women's Health, Lung Disease
at Investor's Business Daily - Mon Feb 02, 11:48AM CST
Generic-drug giant Mylan (MYL) announced Monday that it's buying $800 million in assets of an India-based women's-health company. Mylan also bought into a lung-disease drug candidate. Mylan agreed to pay $750 million upfront plus up to $50 million in...
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28)
Theravance Shares Down 58.2% Since SmarTrend's Sell Call (THRX)
Comtex SmarTrend(R) - Wed Jan 28, 9:08AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 6 months, Theravance has returned 58.18% as of today's recent price of $11.43.
THRX: 14.85 (+1.00)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 4:36PM CST
TTS: 8.57 (-0.27), HK: 2.18 (-0.02), BTU: 7.65 (+0.46), IRWD: 15.15 (-0.85), CAG: 34.83 (-1.59), LOGM: 52.22 (+4.17), PES: 5.74 (+0.54), THRX: 14.85 (+1.00), HOS: 20.45 (+1.52), EGY: 5.86 (-0.06)
Theravance: Notes From The Leerink Global Healthcare Conference
Early Retiree - at Seeking Alpha - Fri Feb 13, 9:01AM CST
THRX: 14.85 (+1.00)
5 Things GlaxoSmithKline PLC's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 12, 9:02AM CST
Source: GlaxoSmithKline, Facebook. The fourth quarter was another rough one for U.K.-based pharmaceutical giant GlaxoSmithKline . During the quarter, GlaxoSmithKline saw its revenue tumble 10% to $9.41 billion , inclusive of negative foreign...
JNJ: 99.62 (+1.18), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance to Report Fourth Quarter and Full Year 2014 Financial Results on February 18, 2015
Marketwired - Wed Feb 11, 3:07PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2014 after market close on Wednesday, February 18, 2015.
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
Theravance (THRX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 10, 7:26AM CST
Theravance (THRX) Shares March Higher, Can It Continue?
THRX: 14.85 (+1.00)
Theravance/Glaxo's Asthma Drug Under FDA Panel Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:36PM CST
Theravance (THRX) and partner GlaxoSmithKline's (GSK) asthma drug, Breo Ellipta is scheduled to be reviewed by the FDA's advisory panel on Mar 19, 2015.
OPHT: 51.11 (+0.12), TBPH: 18.51 (+0.28), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00)
Theravance Biopharma: GSK Accelerates Study Of High-Potential COPD Therapy
Early Retiree - at Seeking Alpha - Mon Feb 09, 1:43PM CST
AZN: 69.96 (+0.20), TBPH: 18.51 (+0.28), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
Theravance's asthma NDA BREO ELLIPTA (FF/VI) to be reviewed by the US FDA Advisory Committee
M2 - Mon Feb 09, 6:19AM CST
Respiratory company Theravance (NASDAQ:THRX) said on Friday that the US Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will review the supplemental New Drug Application (NDA) for fluticasone furoate and vilanterol dry powder in asthma patients.
THRX: 14.85 (+1.00)
GSK and Theravance Announce Start of Phase III Lung Function Study With 'Closed' Triple Combination Treatment FF/UMEC/VI for COPD
Marketwired - Mon Feb 09, 4:13AM CST
GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced the start of a second global phase III study to evaluate the effects of the investigational once-daily closed triple combination of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with chronic obstructive pulmonary disease (COPD).
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
FDA Ad Comm to review expanded indication for Glaxo/Theravance COPD drug
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 9:06AM CST
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99)
Theravance Announces FDA Advisory Committee to Review BREO(R) ELLIPTA(R) (FF/VI) for Asthma
Marketwired - Fri Feb 06, 8:10AM CST
Theravance, Inc. (NASDAQ: THRX) today announced that on March 19, 2015, the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee will discuss the supplemental New Drug Application (NDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO(R) ELLIPTA(R)), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older. The advanced display of the Federal Register notice announcing the advisory committee meeting can be found at: http://www.ofr.gov/OFRUpload/OFRData/2015-02554_PI.pdf
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
6.73% Edge For 5 Healthcare Lowest-Priced, High-Yield January Dividend Dogs
Fredrik Arnold - at Seeking Alpha - Thu Feb 05, 6:43PM CST
SNN: 35.82 (-0.28), VIVO: 19.15 (+0.16), PETS: 15.57 (-0.05), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), ABBV: 58.05 (+1.00), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), SNY: 49.42 (+0.82), PDLI: 7.28 (+0.03)
Theravance Royalty Revenue Forecast
Early Retiree - at Seeking Alpha - Thu Feb 05, 4:45PM CST
THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance to Present at the Leerink Global Healthcare Conference
Marketwired - Thu Feb 05, 3:05PM CST
Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 11:10 a.m. EST. The conference will be held from February 11 - 12, 2015 at the Waldorf Astoria, New York, NY.
THRXV: 28.00 (+7.07), THRX: 14.85 (+1.00)
10 Hardy Healthcare Dividend Dogs Hit 20% Mean January Upsides
Fredrik Arnold - at Seeking Alpha - Wed Feb 04, 7:53PM CST
KND: 19.68 (-0.38), BDX: 143.71 (+0.72), VIVO: 19.15 (+0.16), PETS: 15.57 (-0.05), PFE: 34.64 (-0.23), AMGN: 153.48 (+0.30), GSK: 47.94 (+1.99), MSA: 46.51 (+0.21), MR: 27.19 (+0.15), PDLI: 7.28 (+0.03), SNN: 35.82 (-0.28), AZN: 69.96 (+0.20), TRIB: 17.30 (-0.12), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), THRX: 14.85 (+1.00), SNY: 49.42 (+0.82)
GlaxoSmithKline PLC Earnings: Finally Turning a Corner?
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 04, 2:18PM CST
Source: GlaxoSmithKline, Flickr. Normally earning season is a catalyst that can push stocks higher, and which investors eagerly await. For GlaxoSmithKline shareholders, however, earnings season has been an utter nightmare in recent quarters as...
PFE: 34.64 (-0.23), THRX: 14.85 (+1.00), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Theravance Down 57.2% Since SmarTrend Downtrend Call (THRX)
Comtex SmarTrend(R) - Wed Feb 04, 9:34AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 7 months, Theravance has returned 57.15% as of today's recent price of $11.71.
THRX: 14.85 (+1.00)
Critical Alerts For BlackBerry, Canadian Solar, Theravance, Petrobras and Halliburton Released By InvestorsObserver
PR Newswire - Wed Feb 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for BBRY, CSIQ, THRX, PBR and HAL.
PBR: 6.98 (+0.44), BBRY: 10.09 (+0.23), HAL: 44.19 (+1.42), THRX: 14.85 (+1.00), CSIQ: 28.84 (-0.30)
Mylan Makes Deals In Women's Health, Lung Disease
at Investor's Business Daily - Mon Feb 02, 11:48AM CST
Generic-drug giant Mylan (MYL) announced Monday that it's buying $800 million in assets of an India-based women's-health company. Mylan also bought into a lung-disease drug candidate. Mylan agreed to pay $750 million upfront plus up to $50 million in...
ABT: 46.09 (+0.87), MYL: 55.85 (+1.34), GSK: 47.94 (+1.99), THRX: 14.85 (+1.00), TBPH: 18.51 (+0.28)
Theravance Shares Down 58.2% Since SmarTrend's Sell Call (THRX)
Comtex SmarTrend(R) - Wed Jan 28, 9:08AM CST
SmarTrend identified a Downtrend for Theravance (NASDAQ:THRX) on July 18th, 2014 at $27.33. In approximately 6 months, Theravance has returned 58.18% as of today's recent price of $11.43.
THRX: 14.85 (+1.00)
